Shilpa Gupta

Shilpa Gupta is a bladder cancer oncologist who has conducted significant research in novel targeted therapies and combination strategies for urothelial carcinoma. Her work has focused on FGFR inhibitors including erdafitinib and the development of antibody-drug conjugate combinations in bladder cancer. She has been a key contributor to cooperative group bladder cancer trials and has advanced clinical research infrastructure in GU oncology. Her research aims to optimize sequencing of novel therapies for urothelial cancer patients.